JP Morgan annual meeting sparks hot topic on innovative drugs, with AIM VACCINE (06660) leading the way in technological innovation for mRNA rabies vaccines.

Entering 2025, the pharmaceutical sector, which is currently at its performance bottom, valuation bottom, and allocation bottom, is quietly welcoming a recovery spring. Recently, Guoyuan published a research report pointing out that the pharmaceutical sector's performance was greatly affected by anti-corruption measures in 2023, and performance growth has gradually stabilized in 2024. In 2025, the focus is on innovative pharmaceutical companies in major sectors with advanced research and development progress. It is recommended to pay attention to individual stocks in areas such as mergers and acquisitions, group procurement clearance, and undervalued sectors. From January 13th to 16th, at the 43rd Annual J.P. Morgan Global Healthcare Conference, the investment heat of China Meheco Group companies is gradually rising, with innovative drugs and technologies becoming the focus of attention for various pharmaceutical companies. At the conference, Roche announced the deployment of billions of dollars annually for mergers and acquisitions and will continue to search for high-quality assets in China. Pfizer is betting heavily on weight-loss drugs and ramping up merger transactions. Looking ahead, innovation will undoubtedly be the long-term development trend of the pharmaceutical sector. mRNA technology platform demonstrates innovation prowess mRNA rabies vaccine performs exceptionally In recent years, mRNA vaccine technology has shown great market potential due to its rapidity, cost-effectiveness, and flexible design for immunogenicity. Companies that are developing mRNA technology platforms are undoubtedly favored by the investment community. AIM VACCINE (06660) is one of the earliest domestic pharmaceutical companies to develop mRNA vaccine products and possesses an independently developed mRNA vaccine technology platform. This platform has good safety and efficacy clinical data in tens of thousands of people, verifying the reliability of the technology platform. On the mRNA platform, AIM has developed heavyweight vaccines such as mRNA iterative rabies vaccine, mRNA herpes zoster vaccine, mRNA respiratory syncytial virus RSV vaccine, mRNA influenza vaccine, and others. The mRNA herpes zoster vaccine has already submitted a clinical pre-application, and the mRNA respiratory syncytial virus RSV vaccine has received domestic clinical approval and submitted a clinical pre-application to the U.S. FDA. The mRNA rabies vaccine LVRNA001 is undoubtedly one of AIM's most focused heavyweight products. Compared to traditional rabies vaccines (which require four or five doses), the mRNA rabies vaccine only requires two doses to provide 100% safe and effective immune protection, with multiple advantages including rapid production, cost-effectiveness, fewer impurities, and better batch-to-batch consistency. AIM VACCINE Vice President and Chief Research Officer Zhang Fan and AIMVACCINE General Manager Peng Yucai published pre-clinical research data on the mRNA rabies vaccine LVRNA001 in the international academic journal, "npj Vaccines": Just two doses are needed to provide 100% safe and effective immune protection. In terms of effectiveness, protection efficacy tests before and after exposure to dogs and mice showed that LVRNA001 one or two doses of immunization can stimulate the production of protective neutralizing antibodies at a faster rate and with higher levels as compared to the five-dose inactivated vaccine, demonstrating higher protective efficacy against high doses of rabies virus challenge. In terms of safety, repeated dose toxicity studies on crab-eating macaques showed good tolerance for both low and high doses. Additionally, reproductive toxicity studies in rats showed that LVRNA001 administration does not affect pregnancy in rats or their offspring, nor does it produce reproductive or developmental toxicity. Some analysts believe that receiving 1 to 2 doses, as opposed to the current market rabies vaccine that requires 4 to 5 doses, is a leap forward. Furthermore, the faster and higher antibody effectiveness is crucial for preventing the 100% fatality rate rabies virus. Public information shows that multiple companies and research institutions, including AIM VACCINE and CureVac, have developed new mRNA rabies vaccines. Recently, a research team from China Pharmaceutical University published a study in the journal "Molecular Therapy" indicating that mRNA vaccines can induce high levels of virus neutralizing antibodies (VNA), sustained humoral and cellular responses, and immunological memory in cynomolgus monkeys at a low dose. This research once again proves the value of using mRNA technology in the field of rabies prevention. With the new growth cycle of the pharmaceutical sector coming quietly in 2025, AIM VACCINE, a leading old vaccine company with deep commercialization capabilities and a series of new products landing, will also see positive stock price catalysis, forming a dual resonance of fundamental and market valuation upward. According to a recent research report released by Guojing International, AIM is expected to launch 1-2 products annually in the next three years. If the research products are successfully approved for market launch one after another, and if the product's international progress progresses smoothly, it is expected to bring new performance growth points for the company and break through the market ceiling. Using the PS valuation method, the company is given a 3.6 times PS valuation for 2026 and a "buy" rating.